Adaptive Biotechnologies Corp vs Hershey Co — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Hershey Co trades at $183 (market cap $36.56B). The key difference: Hershey Co is far larger — about 9× Adaptive Biotechnologies Corp's market cap, and Hershey Co pays a 3.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HSY | |
|---|---|---|
Market Cap | $4.04B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $236.28 |
52-Week Low | $12.30 | $162.31 |
Enterprise Value | $4.10B | $41.70B |
Dividend Yield | — | 3.19% |
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Hershey (HSY) trades at $184.19, up 0.79% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth remains steady at $11.69 billion for 2025. Technical indicators show bullish momentum with the current price near resistance at $184, supported by positive moving average signals. The company maintains robust profitability with 38.38% gross margins and 32.81% ROE, though net income declined to $883 million in 2025 from previous highs.
HSY presents a favorable risk-reward profile with analyst consensus target of $196.78 offering 7% upside potential. Recent margin recovery from favorable cocoa contracts and dividend growth support bullish sentiment, though volume declines and competitive pressures in salty snacks remain concerns. With 68.57% of analysts maintaining Hold ratings, the stock offers steady growth potential but requires monitoring of consumer demand trends and input cost management.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →